Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Journal of Nuclear Cardiology
Erschienen in: Journal of Nuclear Cardiology 5/2017

01.10.2017 | SPECIAL CONTRIBUTION

Joint SNMMI–ASNC expert consensus document on the role of 18F-FDG PET/CT in cardiac sarcoid detection and therapy monitoring

verfasst von: Panithaya Chareonthaitawee, Rob S. Beanlands, Wengen Chen, Sharmila Dorbala, Edward J. Miller, Venkatesh L. Murthy, David H. Birnie, Edward S. Chen, Leslie T. Cooper, Roderick H. Tung, Eric S. White, Salvador Borges-Neto, Marcelo F. Di Carli, Robert J. Gropler, Terrence D. Ruddy, Thomas H. Schindler, Ron Blankstein

Erschienen in: Journal of Nuclear Cardiology | Ausgabe 5/2017

Einloggen, um Zugang zu erhalten

Excerpt

Sarcoidosis is a systemic disorder of unknown etiology whose clinical presentation is characterized by the heterogeneous contributions of nonnecrotizing granulomatous inflammation and concomitant fibrosis. Cardiac involvement portends an adverse prognosis and may account for approximately 25% of deaths from sarcoidosis. The diagnosis of cardiac sarcoidosis (CS) remains a challenge because of the combination of a nonspecific clinical presentation (e.g., conduction abnormalities, tachy- and bradyarrhythmias, and heart failure) and focal infiltration of granulomas and scarring in the heart, which limit the diagnostic utility of endomyocardial biopsy (EMB). Potentiating these challenges is the fact that data on the benefit of immunosuppressive therapy are limited. …
Literatur
1.
Judson MA, Costabel U, Drent M, et al. The WASOG Sarcoidosis Organ Assessment Instrument: An update of a previous clinical tool. Sarcoidosis Vasc Diffuse Lung Dis. 2014;31:19–27.PubMed
2.
Dumas O, Abramovitz L, Wiley AS, Cozier YC, Camargo CA. Epidemiology of sarcoidosis in a prospective cohort study of U.S. women. Ann Am Thorac Soc. 2016;13:67–71.CrossRefPubMedPubMedCentral
3.
Erdal BS, Clymer BD, Yildiz VO, Julian MW, Crouser ED. Unexpectedly high prevalence of sarcoidosis in a representative U.S. metropolitan population. Respir Med. 2012;106:893–9.CrossRefPubMed
4.
Grunewald J, Spagnolo P, Wahlström J, Eklund A. Immunogenetics of disease-causing inflammation in sarcoidosis. Clin Rev Allergy Immunol. 2015;49:19–35.CrossRefPubMed
5.
Hillerdal G, Nöu E, Osterman K, Schmekel B. Sarcoidosis: Epidemiology and prognosis. Am Rev Respir Dis. 1984;130:29–32.PubMed
6.
Milman N, Selroos O. Pulmonary sarcoidosis in the Nordic countries 1950-1982: Epidemiology and clinical picture. Sarcoidosis. 1990;7:50–7.PubMed
7.
Rybicki BA, Major M, Popovich J, Maliank MJ, Lannuzzi MC. Racial differences in sarcoidosis incidence: A 5-year study in a health maintenance organization. Am J Epidemiol. 1997;145:234–41.CrossRefPubMed
8.
Ungprasert P, Carmona EM, Utz JP, Ryu JH, Crowson CS, Matteson EL. Epidemiology of sarcoidosis 1946-2013: A population-based study. Mayo Clin Proc. 2016;91:183–8.CrossRefPubMed
9.
Baughman RP, Field S, Costabel U, et al. Sarcoidosis in America: Analysis based on health care use. Ann Am Thorac Soc. 2016;13:1244–52.CrossRefPubMed
10.
Morimoto T, Azuma A, Abe S, et al. Epidemiology of sarcoidosis in Japan. Eur Respir J. 2008;31:372–9.CrossRefPubMed
11.
Iwai K, Sekiguti M, Hosoda Y, et al. Racial differences in cardiac sarcoidosis incidence observed at autopsy. Sarcoidosis. 1994;11:26–31.PubMed
12.
Silverman KJ, Hutchins GM, Bulkley BH. Cardiac sarcoid: A clinicopathologic study of 84 unselected patients with systemic sarcoidosis. Circulation. 1978;58:1204–11.CrossRefPubMed
13.
Greulich S, Deluigi CC, Gloekler S, et al. CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis. JACC Cardiovasc Imaging. 2013;6:501–11.CrossRefPubMed
14.
Nagai T, Kohsaka S, Okuda S, Anzai T, Asano K, Fukuda K. Incidence and prognostic significance of myocardial late gadolinium enhancement in patients with sarcoidosis without cardiac manifestation. Chest. 2014;146:1064–72.CrossRefPubMed
15.
16.
Hulten E, Agarwal V, Cahill M, et al. Presence of late gadolinium enhancement by cardiac magnetic resonance among patients with suspected cardiac sarcoidosis is associated with adverse cardiovascular prognosis: A systematic review and meta-analysis. Circ Cardiovasc Imaging. 2016;9:e005001.CrossRefPubMedPubMedCentral
17.
Lagana SM, Parwani AV, Nichols LC. Cardiac sarcoidosis: A pathology-focused review. Arch Pathol Lab Med. 2010;134:1039–46.PubMed
18.
Tavora F, Cresswell N, Li L, Ripple M, Solomon C, Burke A. Comparison of necropsy findings in patients with sarcoidosis dying suddenly from cardiac sarcoidosis versus dying suddenly from other causes. Am J Cardiol. 2009;104:571–7.CrossRefPubMed
19.
Fleming HA. Sarcoid heart disease. Br Med J (Clin Res Ed). 1986;292:1095–6.CrossRef
20.
Matsui Y, Iwai K, Tachibana T, et al. Clinicopathological study on fatal myocardial sarcoidosis. Ann N Y Acad Sci. 1976;278:455–69.CrossRefPubMed
21.
Roberts WC, McAllister HA Jr, Ferrans VJ. Sarcoidosis of the heart. Am J Med. 1977;63:86–108.CrossRefPubMed
22.
Smedema J-P, Snoep G, van Kroonenburgh MPG, et al. Cardiac involvement in patients with pulmonary sarcoidosis assessed at two university medical centers in the Netherlands. Chest. 2005;128:30–5.CrossRefPubMed
23.
Yazaki Y, Isobe M, Hiroe M, et al. Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone. Am J Cardiol. 2001;88:1006–10.CrossRefPubMed
24.
Uusimaa P, Ylitalo K, Anttonen O, et al. Ventricular tachyarrhythmia as a primary presentation of sarcoidosis. Europace. 2008;10:760–6.CrossRefPubMed
25.
Wyplosz B, Marijon E, Dougados J, Pouchot J. Sarcoidosis: An unusual cause of acute pericarditis. Acta Cardiol. 2010;65:83–4.CrossRefPubMed
26.
Dubrey SW, Falk RH. Diagnosis and management of cardiac sarcoidosis. Prog Cardiovasc Dis. 2010;52:336–46.CrossRefPubMed
27.
Ward EV, Nazari J, Edelman RR. Coronary artery vasculitis as a presentation of cardiac sarcoidosis. Circulation. 2012;125:e344–6.CrossRefPubMed
28.
Chiu C-Z, Nakatani S, Zhang G, et al. Prevention of left ventricular remodeling by long-term corticosteroid therapy in patients with cardiac sarcoidosis. Am J Cardiol. 2005;95:143–6.CrossRefPubMed
29.
Hiraga H, Yuwai K, Hiroe M. Diagnostic standard and guidelines for sarcoidosis. Jpn J Sarcoidosis Granulomatous Disord. 2007;27:89–102.
30.
Birnie DH, Sauer WH, Bogun F, et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm. 2014;11:1305–23.CrossRefPubMed
31.
Cooper LT, Baughman KL, Feldman AM, et al. The role of endomyocardial biopsy in the management of cardiovascular disease. Eur Heart J. 2007;28:3076–93.CrossRefPubMed
32.
Kandolin R, Lehtonen J, Graner M, et al. Diagnosing isolated cardiac sarcoidosis. J Intern Med. 2011;270:461–8.CrossRefPubMed
33.
Casella M, Pizzamiglio F, Dello Russo A, et al. Feasibility of combined unipolar and bipolar voltage maps to improve sensitivity of endomyocardial biopsy. Circ Arrhythm Electrophysiol. 2015;8:625–32.CrossRefPubMed
34.
Liang JJ, Hebl VB, DeSimone CV, et al. Electrogram guidance: A method to increase the precision and diagnostic yield of endomyocardial biopsy for suspected cardiac sarcoidosis and myocarditis. JACC Heart Fail. 2014;2:466–73.CrossRefPubMedPubMedCentral
35.
Nery PB, Keren A, Healey J, Leug E, Beanlands RS, Birnie DH. Isolated cardiac sarcoidosis: Establishing the diagnosis with electroanatomic mapping-guided endomyocardial biopsy. Can J Cardiol. 2013;29:1015.e1–3.CrossRef
36.
37.
Youssef G, Leung E, Mylonas I, et al. The use of 18F-FDG PET in the diagnosis of cardiac sarcoidosis: A systematic review and metaanalysis including the Ontario experience. J Nucl Med. 2012;53:241–8.CrossRefPubMed
38.
Eguchi M, Tsuchihashi K, Hotta D, et al. Technetium-99m sestamibi/tetrofosmin myocardial perfusion scanning in cardiac and noncardiac sarcoidosis. Cardiology. 2000;94:193–9.CrossRefPubMed
39.
Le Guludec D, Menad F, Faraggi M, Weinmann P, Battesti J-P, Valeyre D. Myocardial sarcoidosis: Clinical value of technetium-99m sestamibi tomoscintigraphy. Chest. 1994;106:1675–82.CrossRefPubMed
40.
Surasi DS, Manapragada PP, Lloyd SG, Bhambhvani P. Role of multimodality imaging including thallium-201 myocardial perfusion imaging in the diagnosis and monitoring of treatment response in cardiac sarcoidosis. J Nucl Cardiol. 2014;21:849–52.CrossRefPubMed
41.
Futamatsu H, Suzuki J, Adachi S, et al. Utility of gallium-67 scintigraphy for evaluation of cardiac sarcoidosis with ventricular tachycardia. Int J Cardiovasc Imaging. 2006;22:443–8.CrossRefPubMed
42.
Momose M, Kadoya M, Koshikawa M, Matsushita T, Yamada A. Usefulness of 67Ga SPECT and integrated low-dose CT scanning (SPECT/CT) in the diagnosis of cardiac sarcoidosis. Ann Nucl Med. 2007;21:545–51.CrossRefPubMed
43.
Nakazawa A, Ikeda K, Ito Y, et al. Usefulness of dual 67Ga and 99mTc-sestamibi single-photon-emission CT scanning in the diagnosis of cardiac sarcoidosis. Chest. 2004;126:1372–6.CrossRefPubMed
44.
Okayama K, Kurata C, Tawarahara K, Wakabayashi Y, Chida K, Sato A. Diagnostic and prognostic value of myocardial scintigraphy with thallium-201 and gallium-67 in cardiac sarcoidosis. Chest. 1995;107:330–4.CrossRefPubMed
45.
Pellegrino D, Bonab AA, Dragotakes SC, Pitman JT, Mariani G, Carter EA. Inflammation and infection: Imaging properties of 18F-FDG–labeled white blood cells versus 18F-FDG. J Nucl Med. 2005;46:1522–30.PubMed
46.
Blankstein R, Osborne M, Naya M, et al. Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis. J Am Coll Cardiol. 2014;63:329–36.CrossRefPubMed
47.
Blankstein R, Waller AH. Evaluation of known or suspected cardiac sarcoidosis. Circ Cardiovasc Imaging. 2016;9:e000867.CrossRefPubMed
48.
Tung R, Bauer B, Schelbert H, et al. Incidence of abnormal positron emission tomography in patients with unexplained cardiomyopathy and ventricular arrhythmias: The potential role of occult inflammation in arrhythmogenesis. Heart Rhythm. 2015;12:2488–98.CrossRefPubMedPubMedCentral
49.
Ishimaru S, Tsujino I, Takei T, et al. Focal uptake on 18F-fluoro-2-deoxyglucose positron emission tomography images indicates cardiac involvement of sarcoidosis. Eur Heart J. 2005;26:1538–43.CrossRefPubMed
50.
Osborne MT, Hulten EA, Singh A, et al. Reduction in 18F-fluorodeoxyglucose uptake on serial cardiac positron emission tomography is associated with improved left ventricular ejection fraction in patients with cardiac sarcoidosis. J Nucl Cardiol. 2014;21:166–74.CrossRefPubMed
51.
Mehta D, Lubitz SA, Frankel Z, et al. Cardiac involvement in patients with sarcoidosis: Diagnostic and prognostic value of outpatient testing. Chest. 2008;133:1426–35.CrossRefPubMed
52.
Osborne MT, Hulten EA, Murthy VL, et al. Patient preparation for cardiac fluorine-18 fluorodeoxyglucose positron emission tomography imaging of inflammation. J Nucl Cardiol. 2017;24:86–99.CrossRefPubMed
53.
54.
Masuda A, Naya M, Manabe O, et al. Administration of unfractionated heparin with prolonged fasting could reduce physiological 18F-fluorodeoxyglucose uptake in the heart. Acta Radiol. 2016;57:661–8.CrossRefPubMed
55.
Williams G, Kolodny GM. Suppression of myocardial 18F-FDG uptake by preparing patients with a high-fat, low-carbohydrate diet. AJR. 2008;190:W151–6.CrossRefPubMed
56.
Harisankar CN, Mittal BR, Agrawal KL, Abrar ML, Bhattacharya A. Utility of high fat and low carbohydrate diet in suppressing myocardial FDG uptake. J Nucl Cardiol. 2011;18:926–36.CrossRefPubMed
57.
Cheng VY, Slomka PJ, Ahlen M, Thomson LE, Waxman AD, Berman DS. Impact of carbohydrate restriction with and without fatty acid loading on myocardial 18F-FDG uptake during PET: A randomized controlled trial. J Nucl Cardiol. 2010;17:286–91.CrossRefPubMed
58.
Demeure F, Hanin FX, Bol A, et al. A randomized trial on the optimization of 18F-FDG myocardial uptake suppression: Implications for vulnerable coronary plaque imaging. J Nucl Med. 2014;55:1629–35.CrossRefPubMed
59.
Kobayashi Y, Kumita S, Fukushima Y, Ishihara K, Suda M, Sakurai M. Significant suppression of myocardial 18F-fluorodeoxyglucose uptake using 24-h carbohydrate restriction and a low-carbohydrate, high-fat diet. J Cardiol. 2013;62:314–9.CrossRefPubMed
60.
Wykrzykowska J, Lehman S, Williams G, et al. Imaging of inflamed and vulnerable plaque in coronary arteries with 18F-FDG PET/CT in patients with suppression of myocardial uptake using a low-carbohydrate, high-fat preparation. J Nucl Med. 2009;50:563–8.CrossRefPubMed
61.
Asmal AC, Leary WP, Thandroyen F, Botha J, Wattrus S. A dose-response study of the anticoagulant and lipolytic activities of heparin in normal subjects. Br J Clin Pharmacol. 1979;7:531–3.CrossRefPubMedPubMedCentral
62.
Manabe O, Yoshinaga K, Ohira H, et al. The effects of 18-h fasting with low-carbohydrate diet preparation on suppressed physiological myocardial F-fluorodeoxyglucose (FDG) uptake and possible minimal effects of unfractionated heparin use in patients with suspected cardiac involvement sarcoidosis. J Nucl Cardiol. 2016;23:244–52.CrossRefPubMed
63.
Gormsen LC, Christensen NL, Bendstrup E, Tolbod LP, Nielsen SS. Complete somatostatin-induced insulin suppression combined with heparin loading does not significantly suppress myocardial 18F-FDG uptake in patients with suspected cardiac sarcoidosis. J Nucl Cardiol. 2013;20:1108–15.CrossRefPubMed
64.
Bois JP, Chareonthaitawee P. Continuing evolution in preparation protocols for 18FDG PET assessment of inflammatory or malignant myocardial disease. J Nucl Cardiol. 2016. doi:10.​1007/​s12350-016-0477-4.
65.
Morooka M, Moroi M, Uno K, et al. Long fasting is effective in inhibiting physiological myocardial 18F-FDG uptake and for evaluating active lesions of cardiac sarcoidosis. EJNMMI Res. 2014;4:1.CrossRefPubMedPubMedCentral
66.
Gaeta C, Fernandez Y, Pavia J, et al. Reduced myocardial 18F-FDG uptake after calcium channel blocker administration: Initial observation for a potential new method to improve plaque detection. Eur J Nucl Med Mol Imaging. 2011;38:2018–24.CrossRefPubMed
67.
Dilsizian V, Bacharach SL, Beanlands R, et al. ASNC imaging guidelines/SNMMI procedure standard for positron emission tomography (PET) nuclear cardiology procedures. J Nucl Cardiol. 2016;23:1187–226.CrossRefPubMed
68.
Okumura W, Iwasaki T, Toyama T, et al. Usefulness of fasting 18F-FDG PET in identification of cardiac sarcoidosis. J Nucl Med. 2004;45:1989–98.PubMed
69.
DiFilippo FP, Brunken RC. Do implanted pacemaker leads and ICD leads cause metal-related artifact in cardiac PET/CT? J Nucl Med. 2005;46:436–43.PubMed
70.
Ahmadian A, Brogan A, Berman J, et al. Quantitative interpretation of FDG PET/CT with myocardial perfusion imaging increases diagnostic information in the evaluation of cardiac sarcoidosis. J Nucl Cardiol. 2014;21:925–39.CrossRefPubMed
71.
Waller AH, Blankstein R. Quantifying myocardial inflammation using F18-fluorodeoxyglucose positron emission tomography in cardiac sarcoidosis. J Nucl Cardiol. 2014;21:940–3.CrossRefPubMed
72.
Ahmadian A, Pawar S, Govender P, Berman J, Ruberg FL, Miller EJ. The response of FDG uptake to immunosuppressive treatment on FDG PET/CT imaging for cardiac sarcoidosis. J Nucl Cardiol. 2017;24:413–24.CrossRefPubMed
73.
74.
Baughman RP, Teirstein A, Judson M, et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med. 2001;164:1885–9.CrossRefPubMed
75.
Simonen P, Lehtonen J, Kandolin R, et al. F-18-fluorodeoxyglucose positron emission tomography-guided sampling of mediastinal lymph nodes in the diagnosis of cardiac sarcoidosis. Am J Cardiol. 2015;116:1581–5.CrossRefPubMed
76.
Delbeke D, Coleman RE, Guiberteau MJ, et al. Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0. J Nucl Med. 2006;47:885–95.PubMed
77.
Promteangtrong C, Salavati A, Cheng G, Torigian DA, Alavi A. The role of positron emission tomography-computed tomography/magnetic resonance imaging in the management of sarcoidosis patients. Hell J Nucl Med. 2014;17:123–35.PubMed
78.
79.
Teirstein AS, Machac J, Almeida O, Lu P, Padilla ML, Iannuzzi MC. Results of 188 whole-body fluorodeoxyglucose positron emission tomography scans in 137 patients with sarcoidosis. Chest. 2007;132:1949–53.CrossRefPubMed
80.
Hamzeh NY, Wamboldt FS, Weinberger HD. Management of cardiac sarcoidosis in the United States: A Delphi study. Chest. 2012;141:154–62.CrossRefPubMed
81.
Sadek MM, Yung D, Birnie DH, Beanlands RS, Nery PB. Corticosteroid therapy for cardiac sarcoidosis: A systematic review. Can J Cardiol. 2013;29:1034–41.CrossRefPubMed
82.
Kato Y, Morimoto S, Uemura A, Hiramitsu S, Ito T, Hishida H. Efficacy of corticosteroids in sarcoidosis presenting with atrioventricular block. Sarcoidosis Vasc Diffuse Lung Dis. 2003;20:133–7.PubMed
83.
Chapelon-Abric C, de Zuttere D, Duhaut P, et al. Cardiac sarcoidosis: A retrospective study of 41 cases. Medicine (Baltimore). 2004;83:315–34.CrossRef
84.
Bargout R, Kelly RF. Sarcoid heart disease: Clinical course and treatment. Int J Cardiol. 2004;97:173–82.CrossRefPubMed
85.
Baughman RP, Drent M, Kavuru M, et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med. 2006;174:795–802.CrossRefPubMed
86.
Baughman RP, Lower EE. The effect of corticosteroid or methotrexate therapy on lung lymphocytes and macrophages in sarcoidosis. Am Rev Respir Dis. 1990;142:1268–71.CrossRefPubMed
87.
Müller-Quernheim J, Kienast K, Held M, Pfeifer S, Costabel U. Treatment of chronic sarcoidosis with an azathioprine/prednisolone regimen. Eur Respir J. 1999;14:1117–22.CrossRefPubMed
88.
89.
Zabel P, Entzian P, Dalhoff K, Schlaak M. Pentoxifylline in treatment of sarcoidosis. Am J Respir Crit Care Med. 1997;155:1665–9.CrossRefPubMed
90.
Baughman RP, Judson MA, Teirstein A, et al. Presenting characteristics as predictors of duration of treatment in sarcoidosis. QJM. 2006;99:307–15.CrossRefPubMed
91.
92.
Winters SL, Cohen M, Greenberg S, et al. Sustained ventricular tachycardia associated with sarcoidosis: Assessment of the underlying cardiac anatomy and the prospective utility of programmed ventricular stimulation, drug therapy and an implantable antitachycardia device. J Am Coll Cardiol. 1991;18:937–43.CrossRefPubMed
93.
Murtagh G, Laffin LJ, Beshai JF, et al. Prognosis of myocardial damage in sarcoidosis patients with preserved left ventricular ejection fraction: Risk stratification using cardiovascular magnetic resonance. Circ Cardiovasc Imaging. 2016;9:e003738.CrossRefPubMedPubMedCentral
94.
Mc Ardle BA, Birnie DH, Klein R, et al. Is there an association between clinical presentation and the location and extent of myocardial involvement of cardiac sarcoidosis as assessed by 18F-fluorodeoxyglucose positron emission tomography? Circ Cardiovasc Imaging. 2013;6:617–26.CrossRefPubMed
95.
Langah R, Spicer K, Gebregziabher M, Gordon L. Effectiveness of prolonged fasting 18f-FDG PET-CT in the detection of cardiac sarcoidosis. J Nucl Cardiol. 2009;16:801–10.CrossRefPubMed
96.
Tahara N, Tahara A, Nitta Y, et al. Heterogeneous myocardial FDG uptake and the disease activity in cardiac sarcoidosis. JACC Cardiovasc Imaging. 2010;3:1219–28.CrossRefPubMed
97.
Yamagishi H, Shirai N, Takagi M, et al. Identification of cardiac sarcoidosis with 13N-NH3/18F-FDG PET. J Nucl Med. 2003;44:1030–6.PubMed
98.
Ohira H, Tsujino I, Ishimaru S, et al. Myocardial imaging with 18F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in sarcoidosis. Eur J Nucl Med Mol Imaging. 2008;35:933–41.CrossRefPubMed
99.
Aggarwal NR, Snipelisky D, Young PM, Gersh BJ, Cooper LT, Chareonthaitawee P. Advances in imaging for diagnosis and management of cardiac sarcoidosis. Eur Heart J Cardiovasc Imaging. 2015;16:949–58.CrossRefPubMed
Metadaten
Titel
Joint SNMMI–ASNC expert consensus document on the role of 18F-FDG PET/CT in cardiac sarcoid detection and therapy monitoring
verfasst von
Panithaya Chareonthaitawee
Rob S. Beanlands
Wengen Chen
Sharmila Dorbala
Edward J. Miller
Venkatesh L. Murthy
David H. Birnie
Edward S. Chen
Leslie T. Cooper
Roderick H. Tung
Eric S. White
Salvador Borges-Neto
Marcelo F. Di Carli
Robert J. Gropler
Terrence D. Ruddy
Thomas H. Schindler
Ron Blankstein
Publikationsdatum
01.10.2017
Verlag
Springer US
Erschienen in
Journal of Nuclear Cardiology / Ausgabe 5/2017
Print ISSN: 1071-3581
Elektronische ISSN: 1532-6551
DOI
https://doi.org/10.1007/s12350-017-0978-9

Weitere Artikel der Ausgabe 5/2017

Journal of Nuclear Cardiology 5/2017 Zur Ausgabe

Editorial

Has anyone been listening? Post-SPECT MPI referral rates to catheterization

Images that Teach

Cardiac imaging with 18F-fluorodeoxyglucose PET/MRI in hypertrophic cardiomyopathy

Review Article

The elusive role of myocardial perfusion imaging in stable ischemic heart disease: Is ISCHEMIA the answer?

Review Article

A quick glance at selected topics in this issue

Images that Teach

Inflammatory involvement in a patient with Leriche syndrome evaluated by 18F-fluorodeoxyglucose PET/MRI

Original Article

Optimization of temporal sampling for 82rubidium PET myocardial blood flow quantification

Neu im Fachgebiet Kardiologie

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise